| Drug General Information |
| Drug ID |
D0I4VT
|
| Former ID |
DNC012089
|
| Drug Name |
1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H18F3N
|
| Canonical SMILES |
CCCN1CCC(C1)C2=CC(=CC=C2)C(F)(F)F
|
| InChI |
1S/C14H18F3N/c1-2-7-18-8-6-12(10-18)11-4-3-5-13(9-11)14(15,16)17/h3-5,9,12H,2,6-8,10H2,1H3
|
| InChIKey |
YATKXAPVZGTXAR-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[1]
|
| D(3) dopamine receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04024:cAMP signaling pathway
|
|
Serotonergic synapsehsa04020:Calcium signaling pathway
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channelshsa04080:Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic NeuronsWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, Other
|
| References |
| REF 1 | Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). |
|---|
